Company Filing History:
Years Active: 2022-2025
Title: Andrew Thomas Parsons: Innovator in Cancer Treatment
Introduction
Andrew Thomas Parsons is a notable inventor based in Cambridge, MA (US). He has made significant contributions to the field of cancer treatment through his innovative research and development efforts. With a total of 5 patents to his name, Parsons is recognized for his work in synthesizing compounds that target specific cancer mutations.
Latest Patents
One of his latest patents involves the synthesis of a KRAS G12C inhibitor compound. This patent describes an improved, efficient, and scalable process to prepare intermediate compounds, such as 2,2′,2″-(1,3,5,2,4,6-trioxatriborinane-2,4,6-triyl)tris(3-fluorophenol). These compounds are useful for the treatment of KRAS G12C mutated cancers. Another significant patent details a process for preparing 7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione. This process involves several steps, including the admixing of various compounds to form a product mixture that includes Compound A, which is essential for synthesizing AMG 510.
Career Highlights
Andrew Thomas Parsons is currently employed at Amgen Inc., a leading biotechnology company. His work at Amgen focuses on developing innovative therapies that address unmet medical needs, particularly in oncology. His contributions have been instrumental in advancing the understanding and treatment of cancer.
Collaborations
Throughout his career, Parsons has collaborated with several notable professionals, including William Powazinik, Iv, and Marc A Caporini. These collaborations have enhanced his research and contributed to the successful development of his patented compounds.
Conclusion
Andrew Thomas Parsons is a distinguished inventor whose work in cancer treatment has the potential to make a significant impact on patient care. His innovative approaches and collaborations continue to drive advancements in the field of oncology.